Mielografia em cães sadios com o meio de contraste ioversol 240 mg I/ml: Resultados clínicos e radiológicos by Sarmento, Luciana Virgínia Costa et al.
Braz. J. vet. Res. anim. Sci.,
São Paulo, v. 38, n. 2, p. 97-100, 2001.
97
M
Myelography in healthy dogs using ioversol 240 mg
I/ml contrast medium. Clinical and radiological results
Mielografia em cães sadios com o meio de contraste ioversol
240 mg I/ml. Resultados clínicos e radiológicos
Luciana Virgínia Costa SARMENTO1; Eduardo Alberto TUDURY2; Eduardo Luiz Cavalcanti CALDAS2;
Patrícia Karla de Luna MAGALHÃES2; Éricka Rejane Correia ALBUQUERQUE2
SUMMARY
This study aimed to assess the opacification period and diagnostic quality of ioversol 240 mg I/ml in the thoracic and lumbar regions after
intracisternally injected, and evaluate its effects on the nervous system by clinical and neurological examinations. Thirty clinically
normal non-descript dogs without sex distinction, weighing 9-12 kg were divided into three groups of 10 animals each. All the animals
were anaesthetized using diazepam and thiopental sodium. Ioversol was injected at a dose of 0.5ml/kg. Cervical radiographs after 5
minutes to confirm injection of the contrast, and thoracolumbar radiographs after 30, 40, 50 and 60 minutes to evaluate the opacification
period were taken. Clinical and neurological examinations were performed daily until 7, 14 and 28 days for groups I, II and III respectively.
Adverse reactions such as pedal movements, preconvulsive behavior, muscular spasms, apnea, dyspnea, and vomit anxiety were observed
during the myelographic procedure only. Ioversol showed good radiopacity, diffusion and miscibility with the cerebrospinal fluid.
Reduction of costs also was possible since it can be autoclaved. Opacification period with diagnostic value was of 60 minutes in 60% of
thoracic radiographs and in 80% of lumbar radiographs. Ioversol showed low incidence of clinical and neurological alterations. It is
concluded that ioversol 240 mg I/ml is appropriate and safe to be used for myelography in dogs.
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INTRODUCTION
yelography is a spinal cord radiographic study that uses a
contrast medium injected into the subarachnoid space14.
Myelography is indicated if there are neurological altera-
tions and normal survey radiographs; if multiple abnormalities
are evident on survey radiographs; if neurological signs do not
correspond to survey radiographs; to locate and to characterize
a lesion when surgery is needed; if neurological signs recur after
decompressive surgery2,4,5,12 and when the diagnosis of
neurological disease is made by exclusion of spinal cord compres-
sion12. Myelography is contraindicated in patients displaying
signs of convulsion, increased intracranial pressure, dehydration,
virus or bacteria infection, and cutaneous infection on puncture
site9,10,14.
Myelography is an important diagnostic aid of neurolo-
gical diseases. Therefore, researches have studied contrast agents
quality15, neurotoxicity11 and opacification period in the
subarachnoid space3,13,19. The ideal contrast agent for myelogra-
phy should be radiopaque, miscible with cerebrospinal fluid,
non-toxic to the nervous system, water soluble, rapidly absor-
bed, but with skilful time to obtain multiple radiographs, and
affordable17.
Ioversol 240 mg I/ml Optiray® 240a is water soluble, non-
ionic and is indicated for human patient myelography6. Although
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ioversol 240 mg I/ml is still not used normally in animals, researches
using other concentrations have found significant qualities. Ioversol
430 mg I/ml was administered via intrathecal routes to rats (0.93-
2.79 ml/kg), demonstrating less toxicity than iohexol and
iopamidol11, the most commonly used drugs for veterinary
myelography17. In thiopental-anaesthetized dogs, ioversol was
injected at 0.37 and 0.56 ml/kg. No deaths, preconvulsive behavior,
convulsion or abnormal neurologic reflexes occurred 24 hours and
24 days post-injection11. In not anaesthetized monkeys given lumbar
intrathecal injection of 0.33 ml/kg, transient tremors and muscular
fasciculation were observed11.
Etherized rats were given up to a dose of 1,000 mg/kg of
ioversol intracisternally (3 ml/kg of ioversol 320 mg I/ml). No
deaths were observed, but chewing, dyspnea, apnea, hypoactivity
and convulsion occurred16.
Ioversol 320 mg I/ml was injected intracisternally at a
dose of 0.28 to 0.70 ml/kg in dogs. Opacification period considered
diagnostic was between 30-40 minutes15. However, abnormalities
such as limb retraction, tachycardia, transient apnea, tremors and
muscular fasciculation were seen.
The objective of this study was to determine the
neurotoxicity of ioversol by clinical and neurological examinations
during and after myelography. Also determined myelographic
quality and opacification period in the thoracolumbar subarachnoid
space when injected into the cisterna magna.
a Mallinckrodt Medical Inc. Pointe-Claire, Quebec, Canada.
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MATERIAL AND METHOD
A total of thirty clinically normal non-descript dogs
without sex distinction and weighing 9-12 kg of the Animal
Surveylance Center of Recife were used in this study. After clinical
and neurological examinations the dogs were vaccinated and
dewormed. The animals were quarantined for at least 15 days pri-
or to treatment. During this period, if any abnormality was noticed,
the animal was discarded and replaced. Canine commercial food
and water were provided ad libitum. Before the myelography, the
dogs were starved for at least 12 hours. The dorsal cranial cervical
region was clipped and aseptically prepared. Diazepam 0.5% at a
dose of 1 mg/kg and thiopental sodium 2.5% at a dose of 12.5 mg/
kg were used as preanesthetic and anaesthetic protocols. Thiopental
sodium was reinjected when necessary. Endotracheal tube was
used so that ventilation could be possible if necessary. With the
animal in lateral recumbency, ioversol 240 mgI/ml at a dose of
0.5 ml/kg was injected intracisternally and then the head and trunk
were raised to an angle of 45º to facilitate caudal migration of the
contrast to the thoracolumbar subarachnoid space. After 5 minutes
lateral cervical myelogram was obtained to confirm correct
injection and after 30, 40, 50 and 60 minutes thoracolumbar
myelogram was taken to determine the opacification period. While
radiographs were made, the animal was held in a horizontal
position. Qualities characteristics of the contrast agent such as
radiopacity, opacification period and miscibility were determined.
Ioversol was autoclaved at 120ºC during 20 minutes and used in
other myelographic procedures. Clinical and neurological
examinations following myelography were performed daily until
days 7, 14 and 28 for groups I, II and III respectively, with 10
animals each. The animals were divided into groups because
cerebrospinal fluid was also analysed before and after myelography
until these data and the results were presented in a future work.
The diagnostic quality of the contrast until 60 minutes period was
graded as follows: no contrast (total absence of contrast), not
appropriate (not appropriate for diagnosis), and appropriate (when
the contrast columns were perfectly visible allowing diagnosis).
Thoracic and lumbar regions were assessed separately.
RESULTS
In general, ioversol 240 mg I/ml showed adequate
diagnostic quality and miscibility, and excellent subarachnoid
diffusion as well. All cervical radiographs taken five minutes after
injection of ioversol 240 mgI/ml showed the presence of contrast
agent in the subarachnoid space (Fig. 1). These following results
consider a total of 120 thoracolumbar myelograms, 30 myelograms
for each period of time (30, 40, 50 and 60 minutes). Thoracic and
lumbar regions were assessed separately (Tab. 1). At 30 minutes
period at the thoracic region, 10% of the myelograms showed
absence of contrast, 26.6% showed not appropriate opacification
and 63.3% showed appropriate opacification. At the same period
of time at the lumbar region, there were no cases of absence of
contrast, 13.3% were not appropriate and 86.6% were appropriate
for diagnosis. At 40 minutes, no contrast was visualized on 6% of
the myelograms at the thoracic region, 33.3% were not appropriate
and 60% were appropriate. At the lumbar region the results
remained the same as at 30 minutes. At 50 minutes period at the
thoracic region 10% showed no contrast, 33.3% were not
appropriate and 56.6% were appropriate. At the lumbar region,
no cases of absence of contrast were found, 20% did not have
diagnostic value, and 80% were appropriate for diagnosis. At 60
minutes 10% of the thoracic myelograms showed no contrast, in
30% the contrast was present but was not appropriate for diagnosis
and 60% were appropriate for diagnosis. At the lumbar region the
results remained the same as at 50 minutes (Fig. 2).
A total of 92 of 120 thoracolumbar myelograms showed
the dorsal contrast column thicker than the ventral contrast column.
Ioversol 240 mg/ml was repeatedly autoclaved without showing
any radiological quality alteration or turbidity.
Minimum clinical and neurological abnormalities were
found related to the myelographic procedure. Only five of the
30 animals studied showed myelographic complications. Two
animals, one of group I, and another of group II had dyspnea.
Figure 1
Presence of ioversol 240 mg I/ml contrast medium in the cervicothoracic
region at five minutes.
Figure 2
Presence of ioversol 240 mg I/ml contrast medium in the lumbar region
at 60 minutes.
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The one of group II had also vomit anxiety; another animal of
group II presented apnea, and was revived; pedal movements
and preconvulsive behavior were found in one animal of group
III; and muscular spasms were seen in one animal of group I. No
post-myelographic complications were observed until 28 days.
DISCUSSION
The quality of a contrast agent for myelography has to do
not only with its diagnostic quality, but also with the period of
time in which it stays in the subarachnoid space causing least
adverse reactions. When the contrast is injected intracisternally, it
takes 10 to 15 minutes to arrive at the thoracic region13. In this
experiment, myelograms started to be processed only at 30 minutes.
So the fact that there were some cases of not appropriate
myelograms for diagnosis at 30 minutes at the thoracic region
(26,6%); myelograms with ioversol 240 mg/ml should be taken
between 15 and 30 minutes after injection to avoid a second
injection of the contrast. Not appropriate opacification at the
thoracic region at 30 minutes can be explained by fast diffusion of
the contrast to the lumbar region15. That was noticed with all the
lumbar myelograms that did not show any case of contrast absence
during the 60 minutes studied. At the lumbar region, it was expected
that the contrast would be present after 30 minutes (Tab. 1), but
with diagnostic quality only until 40 minutes as reported Tudury
et al.15 with ioversol 320 mg/ml. Instead, at 60 minutes the
myelograms showed the contrast was still present, whereas 80%
with diagnostic value. Comparing with ioversol 320 mg/ml,
ioversol 240 mg/ml demonstrated more efficiency not only because
of its opacification period, but also its diagnostic quality.
Because of anatomical variation that occurs between the
dorsal and ventral subarachnoid space, when the contrast is
injected, the dorsal contrast column appears to be thicker than the
ventral one7. It was possible to observe this in the majority of the
cases, but not in all of them, due to myelograms with absence of
contrast and not appropriate opacification.
Iodinated non-ionic contrast agents like ioversol can be
autoclaved, supporting well high temperatures without deterioration2.
This is very important when the myelographic procedure is being
done in small animals and not all the contrast is used. The advantage
is that you can lower the costs15, what makes myelography more
affordable to animal owners and, therefore, a procedure that can be
included in the routine of clinics and hospitals.
Similar or more serious abnormalities seen in this
experiment were previously reported using other contrast
mediums1,8,9, using ioversol 320 mg I/ml15,16 and using ioversol
430 mg I/ml11. The low incidence of adverse reactions observed
in this study was expected because ioversol has the highest
hidrophilicity when compared to other contrast agents currently
used for myelography. Ioversol 240 mg I/ml when compared with
other concentrations has lower osmolality and consequently lower
neurotoxicity. Apnea was previously reported using ioversol15,16.
This episode was associated to its pharmacology18 and also with
its interaction with anaesthetics agents. Because of the small
number of dogs presenting complications, the authors of this work
considered the individuality of each animal also responsible for
these complications.
CONCLUSIONS
The opacification period with diagnostic value of ioversol
240 mg I/ml contrast medium injected intracisternally was of 60
minutes in 60% of thoracic radiographs and in 80% of lumbar
radiographs. The stability of the contrast to heat when autoclaved
was confirmed and cost reduction was possible. Minimum adverse
reactions were observed. The contrast demonstrated adequate
radiopacity, diffusion and miscibility with cerebrospinal fluid. It
is concluded that ioversol 240 mg I/ml is appropriate and safe to
be used for myelography in dogs.
RESUMO
Este trabalho teve por objetivo avaliar o período de opacificação e a qualidade diagnóstica do ioversol 240 mg I/ml, nas regiões torácica
e lombar após sua injeção na cisterna magna, e verificar seus efeitos sobre o sistema nervoso por meio de observações clínicas e neuro-
lógicas. Utilizaram-se 30 cães sadios, sem distinção de sexo ou raça, com peso entre 9 e 12 kg, divididos em três grupos de 10 animais
cada. Nos animais anestesiados com diazepam e tiopental sódico, o ioversol foi injetado na dose de 0,5 ml/kg. Foram obtidas radiografias
cervicais aos cinco minutos para confirmar a injeção do contraste e toracolombares aos 30, 40, 50 e 60 minutos para avaliar o período de
opacificação. Exames clínicos e neurológicos foram realizados diariamente até os 7, 14 e 28 dias para os grupos I, II e III respectivamente.
Efeitos adversos como movimentos de pedalagem, início de convulsão, espasmos musculares, apnéia, dispnéia e ânsia de vômito foram
observados apenas durante o procedimento mielográfico. O ioversol apresentou boas radiopacidade, difusão e miscibilidade com o
Radiographic Time (Minutes)
30 40 50 60
Diagnostic
Quality
T* L** T L T L T L
No Contrast 3 0 2 0 3 0 3 0
Not
Appropriate
8 4 10 4 10 6 9 6
Appropriate 19 26 18 26 17 24 18 24
Table 1
Diagnostic quality of ioversol contrast medium expressed in number of
animals related to radiographic time and spine regions. Recife  PE,
1999.
* T: thoracic region; **L: lumbar region.
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líquor, oferecendo também a possibilidade de redução de custos, já que pode ser autoclavado. O tempo de opacificação do contraste com
valor diagnóstico atingiu 60 minutos em 60% das radiografias torácicas e em 80% das radiografias lombares. Havendo baixa incidência
de alterações clínicas e neurológicas, e apropriadas qualidades radiográficas, concluiu-se que o ioversol na concentração de 240 mg I/ml
é adequado e seguro para ser utilizado em mielografia de cães.
UNITERMOS: Mielografia; Cães; Meios de contraste.
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